Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
SPGI$449.33+0.40(+0.09%)Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600 Huron Consulting Group Inc. (NASD: HURN) will replace Supernus Pharmaceuticals Inc. (NASD: SUPN) in the S&P SmallCap 600 before the opening of...[5:43:00 PM ET]ASTL$4.800.00(0.00%)Algoma Steel Group Inc. Reports Financial Results for the Three Months Ended September 30, 2026[5:30:00 PM ET]WFG$68.25-1.41(-2.02%)West Fraser Announces Third Quarter 2026 Results and Indefinite Curtailments in its OSB and Lumber Portfolios West Fraser Timber Co. Ltd. ("West Fraser" or the "Company") (TSX and NYSE: WFG) reported today the third quarter results of 2026 ("Q3-26"). The...[5:30:00 PM ET]LOGI$98.27-13.55(-12.12%)Logitech Files Quarterly Report on Form 10-Q[5:24:00 PM ET]STBA$50.48-0.11(-0.22%)S&T Bancorp, Inc. Increases Quarterly Cash Dividend The Board of Directors of S&T Bancorp, Inc. (S&T) (NASDAQ: STBA), the holding company for S&T Bank, approved a $0.38 per share cash dividend on...[5:20:00 PM ET]EPAC$35.70+0.34(+0.96%)Enerpac Tool Group Reports Fourth Quarter and Full-Year Fiscal 2026 Results; Introduces Fiscal 2027 Outlook[5:15:00 PM ET]YEAR$50.16-0.01(-0.02%)CORE LAB REPORTS THIRD QUARTER 2026 RESULTS:[5:15:00 PM ET]NVRVF$0.130.00(0.00%)Novra Announces $1.3 Million Private Placement[5:15:00 PM ET]JOB$0.19-0.02(-10.63%)GEE Group Inc. Announces Effective Date of Previously Approved Reverse Stock Split[5:10:00 PM ET]BLNK$0.41+0.02(+5.88%)Blink Charging to Host Third Quarter Conference Call on Thursday, November 5, 2026[5:07:00 PM ET]BTRMF$0.12+0.00(+4.43%)Battery Mineral Resources Corp. Announces Proposed C$17 Million Private Placement[5:05:00 PM ET]

TPST · NASDAQ

Tempest Therapeutics, Inc.

$0.51 0.00 (-0.25%)

Company overview

Tempest Therapeutics Inc. is a clinical-stage oncology company that develops small molecule therapeutics to treat cancer. Its two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4 receptors of prostaglandin E2 currently in a Phase 1 trial for solid tumors, and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha also in a Phase 1 trial for solid tumors. The company also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California. It was formerly a subsidiary of Inception Sciences, Inc.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$8.6M
Employees
24
Headquarters
Brisbane, CA
Website
tempesttx.com
CEO
Matthew Angel
Listed
November 12, 2012
P/E
-0.08
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$22.2M
Operating income
-$43.4M
EBITDA
-$42.9M
Net income
-$43.1M
EPS
-$6.21
Total assets
$10.7M
Total debt
$7.9M
Earnings yield
-1,217.65%

Price chart

0.430.891.341.792.25
TPST 1D NASDAQ O0.52H0.53L0.51C0.51+0.00 (+0.10%)Vol79.23K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
TPSTTempest Therapeutics, Inc. Press release Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise GlobeNewswire
TPSTTempest Therapeutics, Inc. Press release Tempest Appoints Global Finance Leader Nancy Freda-Smith to GlobeNewswire
TPSTTempest Therapeutics, Inc. Stock news Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket Benzinga
TPSTTempest Therapeutics, Inc. Press release Tempest Secures Exclusive Option to License Clinical-Stage GlobeNewswire
TPSTTempest Therapeutics, Inc. Press release Tempest Therapeutics Announces Up to $7.5 Million Private Placement GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference GlobeNewswire
TPSTTempest Therapeutics, Inc. Press release Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest Presents Clinical Update at ISCT 2026 Annual Meeting GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T GlobeNewsWire
TPSTTempest Therapeutics, Inc. Press release Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts GlobeNewsWire
TPSTTempest Therapeutics, Inc. Stock news New Strong Buy Stocks for April 10th Zacks Investment Research
TPSTTempest Therapeutics, Inc. Press release Tempest Reports Year End 2025 Financial Results and Provides Business Update GlobeNewsWire
TPSTTempest Therapeutics, Inc. Stock news Matthew Angel Purchases 231,482 Shares of Tempest Therapeutics (NASDAQ:TPST) Stock Defense World
TPSTTempest Therapeutics, Inc. Stock news Tempest Therapeutics (TPST) Projected to Post Quarterly Earnings on Wednesday Defense World
See more
FAQ

Questions about Tempest Therapeutics, Inc.

What does Tempest Therapeutics, Inc. do?
Tempest Therapeutics Inc. is a clinical-stage oncology company that develops small molecule therapeutics to treat cancer. Its two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4 receptors of prostaglandin E2 currently in a Phase 1 trial for solid tumors, and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha also in a Phase 1 trial for solid tumors. The company also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California. It was formerly a subsidiary of Inception Sciences, Inc.
What is TPST's market cap?
Tempest Therapeutics, Inc. (TPST) is a listed stock with a live quote. The latest market cap on this page is $8.6M.
Where is Tempest Therapeutics, Inc. headquartered?
Tempest Therapeutics, Inc. is headquartered in Brisbane, CA.
How do I get TPST news from the API?
Call GET /v1/news?tickers=TPST. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does TPST news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for TPST, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the TPST price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs